title: [Bone metastasis of prostatic cancer imitating Paget's sarcoma].
abstract: METHODS
  A 74-year-old man presented with bone pain of the right hip, night sweat and weight loss for 18 months. The diagnosis of Paget's disease was confirmed four months before admission, but pain and elevated serum alkaline phosphatase levels remained despite treatment with i.v. bisphosphonates. The physical examination showed no specific abnormalities.
  
  
  METHODS
  Laboratory findings were elevated levels of serum alkaline phosphatase (AP), CA 19-9 and CEA. Radiological and tomographic images showed an aggressive periostal reaction consistent with Paget's sarcoma. The bone biopsy revealed the presence of prostatic cancer which was confirmed in a subsequent prostate biopsy.
  
  
  METHODS
  Because of the multiple bone and lung metastases the disease proved to be incurable and the patient received palliative therapy with flutamide. He died 12 months later.
  
  
  CONCLUSIONS
  In patients with Paget's disease lacking of response to bisphosphonate administration (permanently increased AP and sustained pain) radiological and clinical re-assessment of the diagnosis is indicated and may sometimes also include bone biopsy.
authors.affiliation: Medizinische Klinik I, Sektion Osteologie, Ruprecht-Karls Universität Heidelberg, 69120 Heidelberg.
authors.forename: C
authors.initials: C
authors.lastname: Metzner
authors.forename: G
authors.initials: G
authors.lastname: Nöldge
authors.forename: G
authors.initials: G
authors.lastname: Delling
authors.forename: U
authors.initials: U
authors.lastname: Oehler
authors.forename: P
authors.initials: P
authors.lastname: Nawroth
authors.forename: C
authors.initials: C
authors.lastname: Kasperk
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D010001:Osteitis Deformans / Q000175:diagnosis* / Q000188:drug therapy; D010166:Palliative Care; D010384:Pelvic Bones / Q000000981:diagnostic imaging / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D011859:Radiography; D017211:Treatment Failure
chemical_list: D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005485:Flutamide